Trials / Active Not Recruiting
Active Not RecruitingNCT04183166
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
A Randomized Phase I/II Trial in Patients With Newly Diagnosed, Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Evaluating a Mutanome-directed Immunotherapy.
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Transgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG4050 | Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks |
Timeline
- Start date
- 2019-12-12
- Primary completion
- 2027-12-30
- Completion
- 2031-12-30
- First posted
- 2019-12-03
- Last updated
- 2026-01-16
Locations
14 sites across 4 countries: United States, France, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04183166. Inclusion in this directory is not an endorsement.